Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor

On Monday, CytoMed Therapeutics GDTC stock is down 6.35% at $3.23 at last check Monday.The Singapore-based clinical-stage biopharmaceutical entered into a five-year Business & Research Collaboration Agreement (BRCA) with India-based SunAct Cancer Institute Private.The BRCA will explore the safety, tolerability, potency, and efficacy of CytoMed’s proprietary allogeneic gamma delta T cells for various cancers (including solid tumors). The human clinical research trial includes a Phase 2 investigator-initiated ...